Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 May 31:2016:bcr2015213179.
doi: 10.1136/bcr-2015-213179.

Is rituximab an effective treatment of refractory calcinosis?

Maria Dubos  1 , Kim Ly  1 , Clothilde Martel  1 , Anne Laure Fauchais  1
Affiliations
Case Reports

Is rituximab an effective treatment of refractory calcinosis?

Maria Dubos et al. BMJ Case Rep. .

Abstract

Calcinosis, the deposition of calcified material in soft tissues, is frequently seen in systemic sclerosis and dermatomyositis. Treatment options are limited, with disappointing results. Some recent case reports suggest that rituximab may be an attractive therapeutic option. In case 1, a 54-year-old woman who presented with rheumatoid arthritis in association with scleromyositis was treated with rituximab for rheumatoid arthritis. Despite this, she developed multiple progressive calcinosis, necessitating extracorporeal shock wave lithotripsy to limit calcinosis extension and pain. In case 2, a 38-year-old man, previously treated for an anti-Pm/Scl-positive polymyositis/scleroderma overlap syndrome, presented with multiple tumoural periarticular calcinosis, which progressed despite bisphosphonates, sodium thiosulfate and thalidomide. We decided to start rituximab. Progression of calcinosis was still evident 6 and 12 months after anti-CD20 treatment. Many treatments have been tried to treat calcinosis without demonstrated effectiveness. Presently, rituximab cannot be recommended for this indication in the absence of successful controlled trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Persistent finger calcinosis despite annual treatment with rituximab and lithotripsy.
Figure 2
Figure 2
Widespread calcinosis after 1 year of rituximab. Calcification before (A, right part) and after (A left part, B) riruximab treatment.
See this image and copyright information in PMC

References

    1. Battistella M, Cribier B. Les calcinoses cutanées. Rev Rhum Monogr 2011;78:178–86. 10.1016/j.monrhu.2011.04.004 - DOI
    1. Reiter N, El-Shabrawi L, Leinweber B et al. . Calcinosis cutis: part I. Diagnostic pathway. J Am Acad Dermatol 2011;65:1–12, quiz 13–4 10.1016/j.jaad.2010.08.038 - DOI - PubMed
    1. Boulman N, Slobodin G, Rozenbaum M et al. . Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805–12. 10.1016/j.semarthrit.2005.01.016 - DOI - PubMed
    1. Reiter N, El-Shabrawi L, Leinweber B et al. . Calcinosis cutis: part II. Treatment options. J Am Acad Dermatol 2011;65:15–22. 10.1016/j.jaad.2010.08.039 - DOI - PubMed
    1. Bienvenu B. [Treatment of subcutaneous calcinosis in systemic disorders]. Rev Med Interne 2014;35:444–52. 10.1016/j.revmed.2014.04.018 - DOI - PubMed

Publication types